skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New onset diabetes after transplantation (NODAT): an overview

Review

(2172) Views  (708) Full article downloads

Authors: Pham PT, Pham PM, Pham SV, Pham PA, Pham PC

Published Date May 2011 Volume 2011:4 Pages 175 - 186
DOI: http://dx.doi.org/10.2147/DMSO.S19027

Phuong-Thu T Pham1, Phuong-Mai T Pham2,3, Son V Pham4, Phuong-Anh T Pham5, Phuong-Chi T Pham2,6
1Nephrology Division, Kidney Transplant Program, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA; 2David Geffen School of Medicine at UCLA, Los Angeles, CA; 3Department of Medicine, Greater Los Angeles VA Medical Center, Los Angeles, CA; 4Division of Cardiology, Bay Pines VA Medical Center, Bay Pines, FL; 5Division of Cardiology, Memphis VA Medical Center, Memphis, TN; 6Department of Medicine, Nephrology Division, UCLA Olive View Medical Center, Los Angeles, CA, USA

Abstract: Although renal transplantation ameliorates cardiovascular risk factors by restoring renal function, it introduces new cardiovascular risks including impaired glucose tolerance or diabetes mellitus, hypertension, and dyslipidemia that are derived, in part, from immunosuppressive medications such as calcineurin inhibitors, corticosteroids, or mammalian target of rapamycin inhibitors. New onset diabetes mellitus after transplantation (NODAT) is a serious and common complication following solid organ transplantation. NODAT has been reported to occur in 2% to 53% of all solid organ transplants. Kidney transplant recipients who develop NODAT have variably been reported to be at increased risk of fatal and nonfatal cardiovascular events and other adverse outcomes including infection, reduced patient survival, graft rejection, and accelerated graft loss compared with those who do not develop diabetes. Identification of high-risk patients and implementation of measures to reduce the development of NODAT may improve long-term patient and graft outcome. The following article presents an overview of the literature on the current diagnostic criteria for NODAT, its incidence after solid organ transplantation, suggested risk factors and potential pathogenic mechanisms. The impact of NODAT on patient and allograft outcomes and suggested guidelines for early identification and management of NODAT will also be discussed.

Keywords: new onset diabetes after transplantation (NODAT), cyclosporine, tacrolimus, sirolimus, hepatitis C and diabetes, cytomegalovirus and diabetes




 

Other articles by Dr Phuong-Thu Pham



Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Treating statin-intolerant patients
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
Management of diabetes across the course of disease: minimizing obesity-associated complications
Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
Uncovering undetected hypoglycemic events
Obesity: considerations about etiology, metabolism, and the use of experimental models
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio